Plain-English translation of NCT07092670 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Melanoma treatments have improved dramatically, helping more young women survive this cancer. However, researchers don't yet fully understand how two types of newer melanoma medications—BRAF/MEK inhibitors and immune checkpoint inhibitors—might affect a woman's fertility and egg quality. This study will follow young women receiving these treatments to learn whether doctors should discuss fertility preservation options before starting therapy.
While older chemotherapy drugs are known to harm fertility, there's very little information about how these newer, targeted cancer medications affect reproductive health. This study aims to fill that gap so doctors can have informed conversations with young patients about protecting their fertility before starting treatment.
You likely qualify if…
You likely don't qualify if…
You would be part of one of three groups: receiving BRAF/MEK inhibitors, receiving immune checkpoint inhibitors, or being observed without these specific treatments. Throughout the study, you would share information about your medical history, treatment details, and reproductive health through follow-up visits and assessments. The study will track how your ovarian function and fertility are affected over time while you receive your melanoma care.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Italy